title: [Bitterness of the mixture of clarithromycin dry syrup and carbocisteine preparation--difference between brand name and generic drugs].
abstract: The purpose of this study was to assess the bitterness intensity and pH of the solutions of clarithromycin dry syrup (CAM-DS), carbocisteine preparation (CC), and the concomitant use of both drugs. We conducted 6 types of human gustatory sensation tests with 6 healthy male volunteers. As a result, there was almost no difference in the bitterness intensity of CAM-DS between the branded (the latest and former preparations) and the generic formulations. The bitterness intensity of CAM-DS (the latest and former preparations of the branded as well as the generic formulations) was almost equally enhanced by mixing it with either the branded CC-DS or the branded and the generic carbocisteine granule (CC-Gr). On this occasion, the enhancing the bitterness of the branded CAM-DS (latest and former preparation) was nearly avoided safely by dosage form's changing CC-DS or CC-Gr to the branded CC-Sy. However, unlike the branded CC-Sy, some generic CC-Sy failed to suppress the bitterness. Furthermore, it was proven that some generic CAM-DS were shown to exhibit bitterness when mixed with even branded CC-Sy. In conclusion, it should be noted that the extent of bitterness of the mixture of CAM-DS and CC highly varies among the generic formulations.
authors.affiliation: Incorporated Foundation of Wadoukai Pharmacy, Tokyo, Japan.
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Matsuo
authors.forename: Syouko
authors.initials: S
authors.lastname: Tanaka
authors.forename: Michiko
authors.initials: M
authors.lastname: Kanou
authors.forename: Kimiko
authors.initials: K
authors.lastname: Isono
authors.forename: Yasuha
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Tomoko
authors.initials: T
authors.lastname: Taura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Asada
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Akamine
authors.forename: Hashimu
authors.initials: H
authors.lastname: Sawai
authors.forename: Masakazu
authors.initials: M
authors.lastname: Kinosita
authors.forename: Tomomi
authors.initials: T
authors.lastname: Sudou
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Kunoki
authors.forename: Akiko
authors.initials: A
authors.lastname: Miki
authors.forename: Satoko
authors.initials: S
authors.lastname: Hori
authors.forename: Hiroki
authors.initials: H
authors.lastname: Satoh
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Ohtani
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Sawada
mesh_terms: D000900:Anti-Bacterial Agents; D002233:Carbocysteine; D002626:Chemistry, Pharmaceutical; D017291:Clarithromycin; D004304:Dosage Forms; D004338:Drug Combinations; D004339:Drug Compounding; D016568:Drugs, Generic; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D013649:Taste; D013652:Taste Threshold
chemical_list: D000900:Anti-Bacterial Agents; D004304:Dosage Forms; D004338:Drug Combinations; D016568:Drugs, Generic; D002233:Carbocysteine; D017291:Clarithromycin